* Cara Therapeutics Inc reported a quarterly adjusted loss of 37 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -58 cents. The mean expectation of five analysts for the quarter was for a loss of 27 cents per share. Wall Street expected results to range from -35 cents to -23 cents per share.
* Revenue fell 85.7% to $991.00 thousand from a year ago; analysts expected $1.17 million.
* Cara Therapeutics Inc's reported EPS for the quarter was a loss of 37 cents.
* The company reported a quarterly loss of $20.02 million.
* Cara Therapeutics Inc shares had risen by 27.4% this quarter and lost 55.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 0.7% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "hold"
Wall Street's median 12-month price target for Cara Therapeutics Inc is $1.01 This summary was machine generated from LSEG data August 15 at 04:58 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jan. 1 0001 -0.27 -0.37 Missed
Mar. 31 2024 -0.40 -0.56 Missed
Dec. 31 2023 -0.41 -0.59 Missed
Sep. 30 2023 -0.52 -0.52 Met
Comments